サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1301022

薬剤デバイス組み合わせ製品の市場規模、シェア、動向分析レポート：製品別（経皮パッチ、輸液ポンプ、吸入器、薬剤溶出ステント）、地域別、セグメント予測、2023年～2030年

Drug Device Combination Products Market Size, Share & Trends Analysis Report By Product (Transdermal Patches, Infusion Pumps, Inhalers, Drug Eluting Stents), By Region, And Segment Forecasts, 2023 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 105 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
薬剤デバイス組み合わせ製品の市場規模、シェア、動向分析レポート：製品別（経皮パッチ、輸液ポンプ、吸入器、薬剤溶出ステント）、地域別、セグメント予測、2023年～2030年
出版日: 2023年06月12日
発行: Grand View Research
ページ情報: 英文 105 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

薬剤デバイス組み合わせ製品市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界の薬剤デバイス組み合わせ製品市場規模は2030年までに2,518億米ドルに達し、予測期間中にCAGR 8.9％で成長すると予測されています。

低侵襲技術に関連する患者の転帰の向上による需要の高まりが、この市場のインパクトの大きい促進要因です。これらのデバイスは早期診断を容易にし、外科手術の大部分において治療期間を短縮します。需要の高まりは、これらの機器によってもたらされる最小限の痛み、コスト効率の向上、安全性の改善、有効性の向上、迅速な回復、入院期間の短縮の結果でもあります。

市販前承認のために明確に定義されたプロトコルを施行する規制ヘルスケア当局の存在感が増していることは、メーカーが自社製品の承認を得る上で支えになると予想されます。最近、米国FDAはリーンマネジメントプロセスマッピングアプローチを取り入れ、前述の製品の審査について、よりまとまりのある、合理的で体系的かつ協力的なシステムを構築しました。これらの当局が発行する安全性ガイドラインや勧告は、将来的にこれらの製品の採用を増加させ、予測期間中の全体的な成長を後押しすると推測されます。

体内の意図しない部位での薬物吸収に起因する治療薬に関連する重篤な副作用や薬物相互作用は、標的治療の必要性を誘発し、それによって薬物とデバイスの組み合わせの需要を促進すると予想されます。例えば、レボドパの継続的な投与は、運動変動、ジスキネジア、重篤な代謝変化、神経毒性などの長期的な合併症を引き起こします。このような要因により、薬物とデバイスの組み合わせ製品のように、標的療法に基づく代替品を取り入れることが臨床的に急務となっています。

薬剤デバイス組み合わせ製品市場レポートハイライト

  • 長期的な治療が必要な疾患における薬剤の自己投与に対する需要の増加により、2022年の製品別シェアは経皮吸収型パッチが優位を占める
  • 吸入器セグメントは、慢性疾患の有病率の上昇により、予測期間中に10.3%の有利なCAGRを示すと予測される
  • 北米は、2022年の地域別シェアで40.5%超の最大を占めたが、これは同地域の有力企業別広範な新製品開発活動によるものです。
  • アジア太平洋地域は、ヘルスケア支出の増加と、これらの製品の利点に関する医師の意識レベルの上昇により、今後数年間で有利な速度で成長すると予想されます。
  • 主要市場プレイヤーは、市場浸透を図るため、新製品の上市や販売提携など様々な戦略に取り組んでいます。
  • 高い運用コスト、厳しい規制の枠組み、資本要件により、参入障壁はより高いレベルに保たれています。

目次

第1章 調査手法と範囲

  • 調査手法
  • 調査範囲と前提条件
  • データソースのリスト

第2章 エグゼクティブサマリー

第3章 市場スナップショット

第4章 市場変数、動向、範囲

  • 市場セグメンテーションと範囲
  • 市場促進要因分析
    • 低侵襲ドラッグデリバリーデバイスの需要の増加
    • 技術の進歩
    • ポイントオブケア治療の人気が高まる
    • 政府のヘルスケア機関別一貫した介入
    • 意識レベルの向上
    • 診療報酬制度の改善
  • 市場抑制要因分析
    • 高い関連コスト
    • ドラッグデリバリーにおける技術的課題
  • 普及と成長の見通しマッピング
  • 医薬品デバイスの組み合わせ-SWOT分析、要因別（政治的および法律的、経済的および技術的）
  • 業界分析- ポーター

第5章 薬剤デバイス組み合わせ製品市場：製品の推定・動向分析

  • 医薬品組み合わせ製品市場：製品変動分析
  • 輸液ポンプ
    • 輸液ポンプ市場推計・予測、2018～2030年（10億米ドル）
    • 体積測定
    • 使い捨て
    • 注射器
    • 外来
    • 埋め込み可能
    • インスリン
  • 整形外科用組み合わせ製品
    • 整形外科用組み合わせ製品市場推計・予測、2018～2030年（10億米ドル）
    • 骨移植インプラント
    • 抗生物質骨セメント
  • 光線力学的治療装置
    • 光線力学療法装置市場推計・予測、2018年から2030年（10億米ドル）
  • 経皮パッチ
    • 経皮パッチ市場推計・予測、2018～2030年（10億米ドル）
  • 薬剤溶出ステント
    • 薬剤溶出ステント市場推計・予測、2018～2030年（10億米ドル）
    • 冠状動脈ステント
  • 創傷ケア製品
    • 創傷治療製品市場推計・予測、2018～2030年（10億米ドル）
  • 吸入器
    • 吸入器市場推計・予測、2018～2030年（10億米ドル）
    • 乾燥粉末
    • ネブライザー
    • 定量投与量
  • 抗菌カテーテル
    • 抗菌カテーテル市場推計・予測、2018～2030年（10億米ドル）
    • 泌尿器科
    • 心臓血管
    • その他
  • その他
    • その他の市場推計・予測、2018～2030年（10億米ドル）

第6章 薬剤デバイス組み合わせ製品市場：地域推定・動向分析、製品別

  • 地域別の薬剤デバイス組み合わせ市場シェア、2022年
  • 北米
    • 製品別、2018～2030年
  • 欧州
    • 製品別、2018～2030年
  • アジア太平洋地域
    • 製品別、2018～2030年
  • ラテンアメリカ
    • 製品別、2018～2030年
  • MEA
    • 製品別、2018～2030年

第7章 競合情勢

  • 戦略の枠組み
  • 市場参加の分類
  • 企業プロファイル
    • Abbott Laboratories
    • Terumo Corporation
    • Stryker Corporation
    • Mylan NV
    • Medtronic
    • St.Jude Medical, Inc.
    • Allergan, Plc
    • Boston Scientific Corporation
    • Novartis AG
    • Teleflex Incorporated
    • CR Bard, Inc.
    • WLCore &Associates, Inc.
図表

List of Tables

  • TABLE 1 Country share estimation
  • TABLE 2 North America drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 3 U.S. drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 4 Canada drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 5 Europe drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 6 Germany drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 7 UK drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 8 France drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 9 Italy drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 10 Spain drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 11 Denmark drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 12 Sweden drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 13 Norway drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 14 Asia Pacific drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 15 Japan drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 16 China drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 17 India drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 18 Australia drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 19 Thailand drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 20 South Korea drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 21 Latin America drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 22 Brazil drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 23 Mexico drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 24 Argentina drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 25 MEA drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 26 South Africa drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 27 Saudi Arabia drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 28 UAE drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 29 Kuwait drug device combination market, by product, 2018 - 2030 (USD Billion)

List of Figures

  • FIG. 1 Market summary (USD Billion)
  • FIG. 2 Market trends & outlook
  • FIG. 3 Market segmentation & scope
  • FIG. 4 Market driver relevance analysis (Current & future impact)
  • FIG. 5 Market restraint relevance analysis (Current & future impact)
  • FIG. 6 Penetration & growth prospect mapping
  • FIG. 7 SWOT analysis, by factor (political & legal, economic and technological)
  • FIG. 8 Porter's five forces analysis
  • FIG. 9 Drug device combination market product outlook key takeaways
  • FIG. 10 Drug device combination market: Product movement analysis
  • FIG. 11 Global infusion pumps market, 2018 - 2030 (USD Billion)
  • FIG. 12 Global volumetric market, 2018 - 2030 (USD Billion)
  • FIG. 13 Global disposable market, 2018 - 2030 (USD Billion)
  • FIG. 14 Global syringe market, 2018 - 2030 (USD Billion)
  • FIG. 15 Global ambulatory market, 2018 - 2030 (USD Billion)
  • FIG. 16 Global implantable market, 2018 - 2030 (USD Billion)
  • FIG. 17 Global insulin market, 2018 - 2030 (USD Billion)
  • FIG. 18 Global orthopedic combination products market, 2018 - 2030 (USD Billion)
  • FIG. 19 Global bone graft implants market, 2018 - 2030 (USD Billion)
  • FIG. 20 Global antibiotic bone cement market, 2018 - 2030 (USD Billion)
  • FIG. 21 Global photodynamic therapy devices market, 2018 - 2030 (USD Billion)
  • FIG. 22 Global transdermal patches market, 2018 - 2030 (USD Billion)
  • FIG. 23 Global drug eluting stents market, 2018 - 2030 (USD Billion)
  • FIG. 24 Global coronary stents market, 2018 - 2030 (USD Billion)
  • FIG. 25 Global peripheral vascular stents market, 2018 - 2030 (USD Billion)
  • FIG. 26 Global wound care products market, 2018 - 2030 (USD Billion)
  • FIG. 27 Global inhalers market, 2018 - 2030 (USD Billion)
  • FIG. 28 Global dry powder market, 2018 - 2030 (USD Billion)
  • FIG. 29 Global nebulizers market, 2018 - 2030 (USD Billion)
  • FIG. 30 Global metered dose market, 2018 - 2030 (USD Billion)
  • FIG. 31 Global antimicrobial catheters market, 2018 - 2030 (USD Billion)
  • FIG. 32 Global urological market, 2018 - 2030 (USD Billion)
  • FIG. 33 Global cardiovascular market, 2018 - 2030 (USD Billion)
  • FIG. 34 Global others market, 2018 - 2030 (USD Billion)
  • FIG. 35 Global others market, 2018 - 2030 (USD Billion)
  • FIG. 36 Regional market place: Key takeaways
  • FIG. 37 Regional outlook, 2015 & 2024
  • FIG. 38 North America drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 39 U.S. drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 40 Canada drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 41 Europe drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 42 Germany drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 43 UK drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 44 France drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 45 Italy drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 46 Spain drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 47 Denmark drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 48 Sweden drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 49 Norway drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 50 Asia Pacific drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 51 Japan drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 52 China drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 53 India drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 54 Australia drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 55 Thailand drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 56 South Korea drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 57 Latin America drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 58 Brazil drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 59 Mexico drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 60 Argentina drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 61 MEA drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 62 South Africa drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 63 Saudi Arabia drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 64 UAE drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 65 Kuwait drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 66 Strategy framework
  • FIG. 67 Participant categorization
目次
Product Code: GVR-1-68038-260-0

Drug Device Combination Products Market Growth & Trends

The global drug device combination product market size is expected to reach USD 251.8 billion by 2030, according to a new report by Grand View Research, Inc., growing at a CAGR of 8.9% during the forecast period. Rising demand for minimally invasive techniques due to enhanced patient outcomes associated with it is the high impact-rendering driver of this market. These devices facilitate early diagnosis and reduce treatment duration in a majority of surgical procedures. Growing demand is also a consequence of minimal pain, heightened cost efficiency, improved safety, better efficacy, rapid recovery, and reduced hospital stay rendered by these devices.

Increasing presence of regulatory healthcare authorities enforcing clearly defined protocols for premarket authorizations is anticipated to support manufacturers in gaining approvals for their products. Recently, the U.S. FDA incorporated the lean management process mapping approach to build a more cohesive, streamlined, systematic, and collaborative system for the review of the aforementioned products. Safety guidelines and recommendations issued by these authorities are presumed to increase the adoption of these products in future and boost overall growth during the forecast period.

Severe side effects and drug interactions associated with therapeutics owing to drug absorption by unintended sites in the body are anticipated to induce need for targeted therapy, thereby propelling demand for drug-device combinations. For instance, consistent administration of Levodopa results in long-term complications such as motor fluctuations, dyskinesias, severe metabolic changes, and neurotoxic effects. These aforementioned factors drive the clinical urgency to incorporate alternatives based on targeted therapy, as in case of drug-device combination products.

Drug Device Combination Products Market Report Highlights

  • Transdermal patch held the dominant share by product in 2022 owing to increasing demand for self-administration of drugs in diseases requiring long-term treatment
  • The inhalers segment is anticipated to exhibit a lucrative CAGR of 10.3% over the forecast period owing to rising prevalence of chronic diseases
  • North America held the largest share of over 40.5% in 2022 in terms of region owing to extensive new product development activities conducted by prominent players across this region
  • Asia Pacific is anticipated to grow at a lucrative rate over the coming years owing to increasing healthcare spending and rising awareness levels of physicians pertaining to benefits of these products
  • Key market players are engaged in various strategies such as new product launch and distribution agreements to gain market penetration
  • High operational cost, stringent regulatory framework, and capital requirement keep entry barriers at a higher level, owing to which, threat of new entrants is expected to be low.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Scope & Assumptions
  • 1.3. List of Data Sources

Chapter 2. Executive Summary

Chapter 3. Market Snapshot

Chapter 4. Market Variables, Trends & Scope

  • 4.1. Market segmentation & scope
  • 4.2. Market Driver Analysis
    • 4.2.1. Increasing demand for minimally invasive drug delivery devices
    • 4.2.2. Technological advancements
    • 4.2.3. Growing popularity of point of care treatment
    • 4.2.4. Consistent interventions by government healthcare organizations
    • 4.2.5. Increasing awareness levels
    • 4.2.6. Improving medical reimbursement framework
  • 4.3. Market Restraint Analysis
    • 4.3.1. High associated costs
    • 4.3.2. Technical challenges in drug delivery
  • 4.4. Penetration & Growth Prospect Mapping
  • 4.5. Drug Device Combination - SWOT Analysis, By Factor (political & legal, economic and technological)
  • 4.6. Industry Analysis - Porter's

Chapter 5. Drug Device Combination Products Market: Product Estimates & Trend Analysis

  • 5.1. Drug device combination market: Product Movement Analysis
  • 5.2. Infusion Pumps
    • 5.2.1. Infusion pumps market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 5.2.2. Volumetric
      • 5.2.2.1. Volumetric market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 5.2.3. Disposable
      • 5.2.3.1. Disposable market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 5.2.4. Syringe
      • 5.2.4.1. Syringe market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 5.2.5. Ambulatory
      • 5.2.5.1. Ambulatory market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 5.2.6. Implantable
      • 5.2.6.1. Implantable market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 5.2.7. Insulin
      • 5.2.7.1. Insulin market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 5.3. Orthopedic Combination Products
    • 5.3.1. Orthopedic combination products market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 5.3.2. Bone graft implants
      • 5.3.2.1. Bone graft implants market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 5.3.3. Antibiotic bone cement
      • 5.3.3.1. Antibiotic bone cement market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 5.4. Photodynamic Therapy Devices
    • 5.4.1. Photodynamic therapy devices market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 5.5. Transdermal Patches
    • 5.5.1. Transdermal patches market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 5.6. Drug Eluting Stents
    • 5.6.1. Drug eluting stents market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 5.6.2. Coronary stents
      • 5.6.2.1. Coronary stents market estimates and forecasts, 2018 - 2030 (USD Billion)
      • 5.6.2.2. Peripheral vascular stents market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 5.7. Wound Care Products
    • 5.7.1. Wound care products market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 5.8. Inhalers
    • 5.8.1. Inhalers market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 5.8.2. Dry powder
      • 5.8.2.1. Dry powder market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 5.8.3. Nebulizers
      • 5.8.3.1. Nebulizers market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 5.8.4. Metered dose
      • 5.8.4.1. Metered dose market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 5.9. Antimicrobial Catheters
    • 5.9.1. Antimicrobial catheters market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 5.9.2. Urological
      • 5.9.2.1. Urological market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 5.9.3. Cardiovascular
      • 5.9.3.1. Cardiovascular market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 5.9.4. Others
      • 5.9.4.1. Others market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 5.10. Others
    • 5.10.1. Others market estimates and forecasts, 2018 - 2030 (USD Billion)

Chapter 6. Drug Device Combination Products Market: Regional Estimates & Trend Analysis, By Product

  • 6.1. Drug Device Combination Market Share By Region, 2022
  • 6.2. North America
    • 6.2.1. North America market estimates and forecasts, by product, 2018 - 2030 (USD Billion)
      • 6.2.1.1. U.S. market estimates and forecasts
      • 6.2.1.2. Canada market estimates and forecasts
  • 6.3. Europe
    • 6.3.1. Europe market estimates and forecasts, by product, 2018 - 2030 (USD Billion)
      • 6.3.1.1. UK market estimates and forecasts
      • 6.3.1.2. Germany market estimates and forecasts
      • 6.3.1.3. France market estimates and forecasts
      • 6.3.1.4. Italy market estimates and forecasts
      • 6.3.1.5. Spain market estimates and forecasts
      • 6.3.1.6. Denmark market estimates and forecasts
      • 6.3.1.7. Sweden market estimates and forecasts
      • 6.3.1.8. Norway market estimates and forecasts
  • 6.4. Asia Pacific
    • 6.4.1. Asia Pacific market estimates and forecasts, by product, 2018 - 2030 (USD Billion)
      • 6.4.1.1. Japan market estimates and forecasts
      • 6.4.1.2. China market estimates and forecasts
      • 6.4.1.3. India market estimates and forecasts
      • 6.4.1.4. Australia market estimates and forecasts
      • 6.4.1.5. Thailand market estimates and forecasts
      • 6.4.1.6. South Korea market estimates and forecasts
  • 6.5. Latin America
    • 6.5.1. Latin America market estimates and forecasts, by product, 2018 - 2030 (USD Billion)
      • 6.5.1.1. Brazil market estimates and forecasts
      • 6.5.1.2. Mexico market estimates and forecasts
      • 6.5.1.3. Argentina market estimates and forecasts
  • 6.6. MEA
    • 6.6.1. MEA market estimates and forecasts, by product, 2018 - 2030 (USD Billion)
      • 6.6.1.1. South Africa market estimates and forecasts
      • 6.6.1.2. Saudi Arabia market estimates and forecasts
      • 6.6.1.3. UAE market estimates and forecasts
      • 6.6.1.4. Kuwait market estimates and forecasts

Chapter 7. Competitive Landscape

  • 7.1. Strategy framework
  • 7.2. Market participation categorization
  • 7.3. Company Profiles
    • 7.3.1. Abbott Laboratories
      • 7.3.1.1. Company overview
      • 7.3.1.2. Financial performance
      • 7.3.1.3. Product benchmarking
      • 7.3.1.4. Strategic initiatives
    • 7.3.2. Terumo Corporation
      • 7.3.2.1. Company overview
      • 7.3.2.2. Financial performance
      • 7.3.2.3. Product benchmarking
      • 7.3.2.4. Strategic initiatives
    • 7.3.3. Stryker Corporation
      • 7.3.3.1. Company overview
      • 7.3.3.2. Financial performance
      • 7.3.3.3. Product benchmarking
      • 7.3.3.4. Strategic initiatives
    • 7.3.4. Mylan N.V.
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Product benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. Medtronic
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Product benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. St.Jude Medical, Inc.
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Product benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. Allergan, Plc
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Product benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. Boston Scientific Corporation
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Product benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. Novartis AG
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Product benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. Teleflex Incorporated
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Product benchmarking
      • 7.3.10.4. Strategic initiatives
    • 7.3.11. C.R. Bard, Inc.
      • 7.3.11.1. Company overview
      • 7.3.11.2. Financial performance
      • 7.3.11.3. Product benchmarking
      • 7.3.11.4. Strategic initiatives
    • 7.3.12. W.L.Core & Associates, Inc.
      • 7.3.12.1. Company overview
      • 7.3.12.2. Financial performance
      • 7.3.12.3. Product benchmarking
      • 7.3.12.4. Strategic initiatives